MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia.
Stam
R W
RW
Hubeek
I
I
den Boer
M L
ML
Buijs-Gladdines
J G C A M
JG
Creutzig
U
U
Kaspers
G J L
GJ
Pieters
R
R
D049109:Cell Proliferation / Q000187:drug effects; D003561:Cytarabine / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004354:Drug Screening Assays, Antitumor; D015321:Gene Rearrangement; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D066298:In Vitro Techniques; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy*; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D008954:Models, Biological; D051788:Myeloid-Lymphoid Leukemia Protein / Q000187:drug effects / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
C497422:KMT2A protein, human; D003561:Cytarabine; D051788:Myeloid-Lymphoid Leukemia Protein; D011495:Histone-Lysine N-Methyltransferase